{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:42:13Z","timestamp":1781073733815,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"am","delay-in-days":318,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["KANT23G0"],"award-info":[{"award-number":["KANT23G0"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007130","name":"University of Texas System","doi-asserted-by":"publisher","award":["250439\/39411"],"award-info":[{"award-number":["250439\/39411"]}],"id":[{"id":"10.13039\/100007130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Cystic Fibrosis Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["1R01HD099756"],"award-info":[{"award-number":["1R01HD099756"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["1R21AI148096"],"award-info":[{"award-number":["1R21AI148096"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["1R01AI179827"],"award-info":[{"award-number":["1R01AI179827"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016048","name":"University of Texas at Tyler","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.tube.2024.102519","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:42:27Z","timestamp":1715600547000},"page":"102519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation"],"prefix":"10.1016","volume":"147","author":[{"given":"Gunavanthi D.","family":"Boorgula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie V.","family":"Philley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8786-8851","authenticated-orcid":false,"given":"Shashikant","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2024.102519_bib1","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/jac\/dkx311","article-title":"Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease","volume":"72","author":"Pasipanodya","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2024.102519_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1128\/AAC.01206-17","article-title":"Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence","volume":"61","author":"Pasipanodya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2024.102519_bib3","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/cid\/cix517","article-title":"Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis","volume":"65","author":"Kwak","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2024.102519_bib4","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.tube.2024.102519_bib5","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2024.102519_bib6","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/jac\/dkz523","article-title":"Repurposing drugs for treatment of Mycobacterium abscessus: a view to a kill","volume":"75","author":"Gumbo","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2024.102519_bib7","doi-asserted-by":"crossref","first-page":"102269","DOI":"10.1016\/j.tube.2022.102269","article-title":"Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"137","author":"Shankar","year":"2022","journal-title":"Tuberculosis"},{"key":"10.1016\/j.tube.2024.102519_bib8","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jac\/dkac068","article-title":"Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses","volume":"77","author":"Chapagain","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2024.102519_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00687-22","article-title":"Omadacycline pharmacokinetics\/pharmacodynamics in the hollow fiber system model and potential combination regimen for short course treatment of Mycobacterium kansasii pulmonary disease","volume":"66","author":"Singh","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2024.102519_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01947-20","article-title":"in vitro susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"65","author":"Brown-Elliott","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2024.102519_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02522-18","article-title":"in vitro activities of omadacycline against rapidly growing mycobacteria","volume":"63","author":"Shoen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2024.102519_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00665-22","article-title":"Efficacy of omadacycline-containing regimen in a mouse model of pulmonary Mycobacteroides abscessus disease","volume":"8","author":"Rimal","year":"2023","journal-title":"mSphere"},{"key":"10.1016\/j.tube.2024.102519_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad335","article-title":"Long term safety and tolerability of omadacycline for the treatment of Mycobacterium abscessus infections","author":"Mingora","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.tube.2024.102519_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa415","article-title":"Omadacycline for the treatment of Mycobacterium abscessus disease: a case series","volume":"7","author":"Pearson","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.tube.2024.102519_bib15","doi-asserted-by":"crossref","first-page":"106847","DOI":"10.1016\/j.ijantimicag.2023.106847","article-title":"Omadacycline pharmacokinetics\/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus Disease","author":"Singh","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.tube.2024.102519_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.790767","article-title":"Omadacycline potentiates clarithromycin activity against Mycobacterium abscessus","volume":"12","author":"Bich Hanh","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.tube.2024.102519_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01704-21","article-title":"Potency of omadacycline against Mycobacteroides abscessus clinical isolates in vitro and in a mouse model of pulmonary infection","volume":"66","author":"Nicklas","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2024.102519_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab002","article-title":"Preliminary, real-world, multicenter experience with omadacycline for Mycobacterium abscessus infections","volume":"8","author":"Morrisette","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.tube.2024.102519_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF02601704","article-title":"Stability of minocycline, doxycycline, and tetracycline stored in agar plates and microdilution trays","volume":"1","author":"Barry","year":"1978","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.tube.2024.102519_bib20","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1128\/AAC.49.9.3903-3909.2005","article-title":"Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method","volume":"49","author":"Bradford","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2024.102519_bib21","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1128\/jcm.31.2.460-462.1993","article-title":"Oxyrase, a method which avoids CO2 in the incubation atmosphere for anaerobic susceptibility testing of antibiotics affected by CO2","volume":"31","author":"Spangler","year":"1993","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.tube.2024.102519_bib22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/jac\/dkaa508","article-title":"in vitro pharmacodynamics of omadacycline against Escherichia coli and","volume":"76","author":"Noel","year":"2021","journal-title":"Acinetobacter baumannii. J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2024.102519_bib23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.drup.2012.04.001","article-title":"Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria","volume":"15","author":"van Ingen","year":"2012","journal-title":"Drug Resist Updates"},{"key":"10.1016\/j.tube.2024.102519_bib24","series-title":"CLSI standard M24","article-title":"Susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes","author":"CLSI","year":"2018"},{"key":"10.1016\/j.tube.2024.102519_bib25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2024.102519_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0962-8479(92)90145-A","article-title":"In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule","volume":"73","author":"Watt","year":"1992","journal-title":"Tuber Lung Dis"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979224000453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979224000453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:55:23Z","timestamp":1778615723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979224000453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":26,"alternative-id":["S1472979224000453"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2024.102519","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2024.102519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102519"}}